PMID- 28766916
OWN - NLM
STAT- MEDLINE
DCOM- 20180522
LR  - 20201019
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 14
IP  - 2
DP  - 2018 Apr
TI  - Interleukin-18 (IL-18) is equally expressed in inflammatory breast cancer and 
      noninflammatory locally advanced breast cancer: A possible association with 
      chemotherapy response.
PG  - e138-e144
LID - 10.1111/ajco.12722 [doi]
AB  - AIM: Inflammatory breast cancer (IBC) is the most aggressive form of locally 
      advanced breast cancer. The signs of inflammation such as hyperemia and 
      hyperthermia might suggest the possible participation of inflammatory mediators. 
      This study investigates stromal and tumor expression of nuclear factor-kappa B 
      (NF-kappaB) and interleukin-18 (IL-18) in samples obtained from IBC and 
      noninflammatory locally advanced breast cancer (LABC) and the influence of these 
      markers on patients' prognosis. METHODS: Demographic data, tumor molecular 
      characteristics and overall survival in both groups were also assessed. 
      Furthermore, in this study, we evaluated the expression of IL-18 and p50 nuclear 
      fraction of NF-kappaB by immunohistochemistry in specimens from IBC and LABC (T4b). 
      RESULTS: We observed that 24.6% of women were diagnosed with IBC up to age 40. In 
      addition, the patients with IBC showed a lower overall survival when compared to 
      LABC. In regard to molecular markers, ER(+) , C-erbB2(-) or triple negative IBC 
      patients showed a significantly reduced overall survival. In addition, a higher 
      IL-18 immunostaining in stroma of IBC and LABC was observed in comparison with 
      tumor cells, but stromal immunoexpression was similar between IBC and LABC. 
      Besides, IL-18 positivity seemed be related with a better clinical response to 
      neoadjuvant chemotherapy. However, NF-kappaB expression was identical in both groups. 
      CONCLUSION: The IL-18 is present in tumor stroma of IBC and LABC and seems to be 
      associated with the complete response to neoadjuvant chemotherapy.
CI  - (c) 2017 John Wiley & Sons Australia, Ltd.
FAU - Aguiar, Marco Antonio Nasser
AU  - Aguiar MAN
AD  - Department of Surgery, Faculty of Medicine, Federal University of Ceara, Brazil.
FAU - Wanderley, Carlos Wagner S
AU  - Wanderley CWS
AD  - Department of Physiology and Pharmacology, Faculty of Medicine, Federal 
      University of Ceara, Brazil.
FAU - Nobre, Livia Maria Soares
AU  - Nobre LMS
AD  - Department of Physiology and Pharmacology, Faculty of Medicine, Federal 
      University of Ceara, Brazil.
FAU - Alencar, Mateus Rolim Mendes
AU  - Alencar MRM
AD  - Department of Physiology and Pharmacology, Faculty of Medicine, Federal 
      University of Ceara, Brazil.
FAU - Saldanha, Maria do Perpetuo Socorro
AU  - Saldanha MDPS
AD  - Cancer Institute of Ceara, Brazil.
FAU - Souza, Alceu Machado
AU  - Souza AM
AD  - Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal 
      University of Ceara, Brazil.
FAU - Wong, Deysi Viviana Tenazoa
AU  - Wong DVT
AD  - Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal 
      University of Ceara, Brazil.
FAU - Barros, Paulo Goberlanio
AU  - Barros PG
AD  - Cancer Institute of Ceara, Brazil.
AD  - Department of Dentistry, University Center Christus.
FAU - Almeida, Paulo Roberto Carvalho
AU  - Almeida PRC
AD  - Department of Pathology and Forensic Medicine, Faculty of Medicine, Federal 
      University of Ceara, Brazil.
FAU - Lima-Junior, Roberto Cesar Pereira
AU  - Lima-Junior RCP
AUID- ORCID: 0000-0002-7033-655X
AD  - Department of Physiology and Pharmacology, Faculty of Medicine, Federal 
      University of Ceara, Brazil.
FAU - Ribeiro, Ronaldo Albuquerque
AU  - Ribeiro RA
AD  - Department of Physiology and Pharmacology, Faculty of Medicine, Federal 
      University of Ceara, Brazil.
AD  - Cancer Institute of Ceara, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20170802
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (IL18 protein, human)
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Inflammatory Breast Neoplasms/drug therapy/*genetics/mortality
MH  - Interleukin-18/*metabolism
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
OTO - NOTNLM
OT  - inflammatory breast cancer
OT  - interleukin-18 (IL-18)
OT  - non-inflammatory locally advanced breast cancer
OT  - nuclear factor-kappa B (NF-kappaB)
EDAT- 2017/08/03 06:00
MHDA- 2018/05/23 06:00
CRDT- 2017/08/03 06:00
PHST- 2017/02/06 00:00 [received]
PHST- 2017/04/28 00:00 [accepted]
PHST- 2017/08/03 06:00 [pubmed]
PHST- 2018/05/23 06:00 [medline]
PHST- 2017/08/03 06:00 [entrez]
AID - 10.1111/ajco.12722 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2018 Apr;14(2):e138-e144. doi: 10.1111/ajco.12722. Epub 
      2017 Aug 2.